Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients
Background: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases. Systemic lupus erythematosus (SLE) is an autoimmune disease with multiple immune dysregulat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=4;spage=347;epage=352;aulast=Eissa |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832544161882963968 |
|---|---|
| author | Eman Eissa Rania Kandil Nehal El-Ghobashy Walaa Abdelfattah Zainab Hammouda Sara Medhat Gadelsayed Faten Bayoumi |
| author_facet | Eman Eissa Rania Kandil Nehal El-Ghobashy Walaa Abdelfattah Zainab Hammouda Sara Medhat Gadelsayed Faten Bayoumi |
| author_sort | Eman Eissa |
| collection | DOAJ |
| description | Background: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases. Systemic lupus erythematosus (SLE) is an autoimmune disease with multiple immune dysregulation. This study aimed to determine PD-1 and PD-L1 expressed levels on both CD3 T and CD19 B lymphocytes in SLE patients compared to healthy donors and their associations with the clinical data and disease activity of those patients.
Patients and Methods: A total of 25 healthy donors and 80 SLE patients were involved in the study. PD-1 and PD-L1 expressed levels on each of CD3 T and CD19 B lymphocytes were determined in the peripheral blood (PB) using flow cytometry.
Results: The expressed levels of PD-1 and PD-L1 on both CD3 T and CD19 B lymphocytes were significantly higher in PB of SLE group than that of controls (P = 0.01, P = 0.001, P = 0.009, and P = 0.001). Significant positive associations were found between PD-1 and PD-L1 expressions on both CD3 T and CD19 B lymphocytes with disease activity in SLE group (P < 0.05).
Conclusion: PD-1 and its ligand PD-L1 could have a role as regulators for immune activation in patients with SLE. |
| format | Article |
| id | doaj-art-db75b90627294d40be05e6ff76ab1391 |
| institution | Kabale University |
| issn | 0973-3698 0973-3701 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Indian Journal of Rheumatology |
| spelling | doaj-art-db75b90627294d40be05e6ff76ab13912025-02-03T10:54:59ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012022-01-0117434735210.4103/injr.injr_241_21Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patientsEman EissaRania KandilNehal El-GhobashyWalaa AbdelfattahZainab HammoudaSara Medhat GadelsayedFaten BayoumiBackground: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases. Systemic lupus erythematosus (SLE) is an autoimmune disease with multiple immune dysregulation. This study aimed to determine PD-1 and PD-L1 expressed levels on both CD3 T and CD19 B lymphocytes in SLE patients compared to healthy donors and their associations with the clinical data and disease activity of those patients. Patients and Methods: A total of 25 healthy donors and 80 SLE patients were involved in the study. PD-1 and PD-L1 expressed levels on each of CD3 T and CD19 B lymphocytes were determined in the peripheral blood (PB) using flow cytometry. Results: The expressed levels of PD-1 and PD-L1 on both CD3 T and CD19 B lymphocytes were significantly higher in PB of SLE group than that of controls (P = 0.01, P = 0.001, P = 0.009, and P = 0.001). Significant positive associations were found between PD-1 and PD-L1 expressions on both CD3 T and CD19 B lymphocytes with disease activity in SLE group (P < 0.05). Conclusion: PD-1 and its ligand PD-L1 could have a role as regulators for immune activation in patients with SLE.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=4;spage=347;epage=352;aulast=Eissab lymphocytesprogrammed cell death 1programmed cell death ligand 1systemic lupus erythematosust lymphocytes |
| spellingShingle | Eman Eissa Rania Kandil Nehal El-Ghobashy Walaa Abdelfattah Zainab Hammouda Sara Medhat Gadelsayed Faten Bayoumi Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients Indian Journal of Rheumatology b lymphocytes programmed cell death 1 programmed cell death ligand 1 systemic lupus erythematosus t lymphocytes |
| title | Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients |
| title_full | Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients |
| title_fullStr | Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients |
| title_full_unstemmed | Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients |
| title_short | Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients |
| title_sort | association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients |
| topic | b lymphocytes programmed cell death 1 programmed cell death ligand 1 systemic lupus erythematosus t lymphocytes |
| url | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2022;volume=17;issue=4;spage=347;epage=352;aulast=Eissa |
| work_keys_str_mv | AT emaneissa associationofdiseaseactivitywithprogrammedcelldeath1anditsligandprogrammedcelldeathligand1expressionsinlupuspatients AT raniakandil associationofdiseaseactivitywithprogrammedcelldeath1anditsligandprogrammedcelldeathligand1expressionsinlupuspatients AT nehalelghobashy associationofdiseaseactivitywithprogrammedcelldeath1anditsligandprogrammedcelldeathligand1expressionsinlupuspatients AT walaaabdelfattah associationofdiseaseactivitywithprogrammedcelldeath1anditsligandprogrammedcelldeathligand1expressionsinlupuspatients AT zainabhammouda associationofdiseaseactivitywithprogrammedcelldeath1anditsligandprogrammedcelldeathligand1expressionsinlupuspatients AT saramedhatgadelsayed associationofdiseaseactivitywithprogrammedcelldeath1anditsligandprogrammedcelldeathligand1expressionsinlupuspatients AT fatenbayoumi associationofdiseaseactivitywithprogrammedcelldeath1anditsligandprogrammedcelldeathligand1expressionsinlupuspatients |